Honoring MG Awareness Month
June marks Myasthenia Gravis (MG) Awareness Month, a time dedicated to amplifying voices, deepening understanding, and advancing care for those living with this rare neuromuscular disorder. That’s why this series brings together expert insights and the latest research to shed light on the complexities of MG.
SPOTLIGHT Registry Findings on Eculizumab and Ravulizumab in gMG
NeuroFrontiersSPOTLIGHT Registry Findings on Eculizumab and Ravulizumab in gMG
BCMA mRNA CAR-T Shows Durable Benefit in MG
NeuroFrontiersBCMA mRNA CAR-T Shows Durable Benefit in MG
RAISE Subgroup Analysis: Zilucoplan Without Prior Rescue Therapy in gMG
NeuroFrontiersRAISE Subgroup Analysis: Zilucoplan Without Prior Rescue Therapy in gMG
Symptom Control in gMG: Comparing Ravulizumab and Efgartigimod
NeuroFrontiersSymptom Control in gMG: Comparing Ravulizumab and Efgartigimod
Christopher A. Scheiner, MD, PhD
How Diagnostic Delays in gMG Impact Disease Severity, Outcomes, and Quality of Life
NeuroFrontiersHow Diagnostic Delays in gMG Impact Disease Severity, Outcomes, and Quality of Life
John A. Morren, MD, FAAN, FAANEM
Quality-of-Life Challenges in gMG Care: Navigating the Invisible Burden
NeuroFrontiersQuality-of-Life Challenges in gMG Care: Navigating the Invisible Burden
Maxwell H. Levy, MD
- advertisement
